USA – Senda Biosciences, a Cambridge, MA-based company that leverages nature to program targeted, potent, and tunable medicines, raised $123M in Series C funding.
The round was led by Flagship Pioneering, with participation from Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, and State of Michigan Retirement System.The company intends to use the funds to drive further development of its proprietary programmable medicines platform and advance its first programs into clinical testing. Led by CEO Guillaume Pfefer, Senda Biosciences is committed to bringing life-changing treatments to patients by harnessing nature’s code to program human cells—both from within and from outside—for targeted, potent, and tunable medicines. Its proprietary platform includes an mRNA engine and the atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life—accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines for infectious, genetic, metabolic, and autoimmune diseases, as well as oncology and powering new frontiers for mRNA therapeutics and vaccines and gene-editing and protein-based therapies.16/08/2022
